The sale of Celerion follows a series of divestments from the H.I.G. Advantage portfolio, which includes the recent exits of St. Croix and United Flow Technologies. These three transactions represent a combined enterprise value exceeding $4.5 billion, signaling a period of high activity for the firm despite broader market volatility. H.I.G. Advantage focuses on acquiring established North American companies with distinct competitive advantages, providing them with operational resources to scale.

Matt Hankins and Rahul Vinnakota, co-heads of the strategy, described the Celerion exit as a validation of their hands-on approach to value creation. Celerion provides early-stage clinical trial solutions and bioanalytical services to pharmaceutical and biotech clients across North America, Europe, and Asia. With $75 billion in capital under management, H.I.G. continues to leverage its global network to execute complex middle-market deals, maintaining a portfolio that currently spans over 100 companies with total sales topping $53 billion.